ClinicalTrials.gg
Active, not recruitingNCT03568318AD UpUpdated Dec 23, 2025Results posted

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Placebo and Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Active, not recruiting at 193 sites in 24 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,533
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
Largest of 17
1,533 · median 272
Started
2018
with 3 others
Phase 3
12 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one has the largest enrollment, is one of 4 that started in 2018, is one of 12 in phase 3, and was the 2nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Read the detailed description

This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, a blinded Long-term Extension (LTE) Period after Week 260 to Week 524, and a 30-day follow-up visit. Participants who meet eligibility criteria in the Main Study will be randomly assigned in a 1:1:1 ratio to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo once daily, in combination with topical corticosteroids.

Upon completion of enrollment of 810 participants in the Main Study, a supplemental study will continue to enroll adolescent participants (Adolescent Sub-study) until a total of 180 adolescent participants are enrolled in the overall study (Main Study + Adolescent Sub-study).

Approximately 1000 participants from M16-045 or M18-891 and approximately 500 participants from M16-047 will have the opportunity to enroll into the blinded Long-Term Extension (LTE) period (Week 260 - Week 524) after reaching Week 260 in their respective studies.

Randomization for the Main Study will be stratified by Baseline disease severity (validated Investigator Global Assessment Scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the Adolescent Sub-study will be stratified by Baseline disease severity (moderate [vIGA-AD 3] versus severe [vIGA-AD 4]) and by geographic region (US/Puerto Rico/Canada and Other).

At Week 16 of both the Main Study and the Adolescent Sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period, and participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose. For the Main Study, the re-randomization will be stratified by Eczema Area and Severity Index (EASI) 50 responder status (Yes/No), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other) and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). For the Adolescent Sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other).

Starting at Week 4, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary The Primary Analysis for the Main Study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the Main Study and the Adolescent Sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Upadacitinib
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and \< 18 years of age
  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline Visit and subject meets Hanifin and Rajka criteria.
  • Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, ≥ 10% of body surface area (BSA) with AD involvement, and weekly average of daily Worst Pruritus numerical rating scale (NRS) ≥ 4.
  • Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
  • Documented history of inadequate response to topical or topical calcineurin inhibitor OR documented systemic treatment for AD within 6 months prior to Baseline Visit

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,533 participants (actual)

Study arms

  • Placebo comparator
    Placebo / Upadacitinib + Topical Corticosteroids

    Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.

    Drug: Placebo · Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)

  • Experimental
    Upadacitinib 15 mg QD + Topical Corticosteroids

    Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.

    Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)

  • Experimental
    Upadacitinib 30 mg QD + Topical Corticosteroids

    Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.

    Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)

  • Experimental
    Long-Term Extension

    Participants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524.

    Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)

Interventions

  • DrugPlacebo

    Tablets taken orally once a day

  • Tablets taken orally once a day

    Also known as: ABT-494, RINVOQ™

  • Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity. Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.

06

What researchers measure

Primary outcomes

  1. Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  2. Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  2. Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  3. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4

  4. Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 4

  5. Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 2

  6. Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 4

  7. Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a ranked secondary endpoint for participants in the Upadacitinib 30 mg + Topical Corticosteroids group versus Placebo + Topical Corticosteroids group only.

    Time frame: Baseline and Week 16

  8. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1

  9. Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  10. Main Study: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  11. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  12. Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

    Time frame: Baseline and Week 16

  13. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  14. Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  15. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4

  16. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 4

  17. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 2

  18. Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 4

  19. Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16

    EASI is used to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. and the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a secondary endpoint for participants in the Upadacitinib 30 mg + TCS group versus Placebo + TCS group only.

    Time frame: Baseline and Week 16

  20. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1

  21. Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  22. Adolescents: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

07

Results

Posted Mar 31, 2022

Participant flow

Participants were enrolled at 171 clinical sites in 22 countries in the Asia-Pacific region, Europe, Middle East, North America, and Oceania. The study included a 16-week double-blind treatment period followed by a blinded extension period (ongoing). The first 810 adults and adolescents enrolled constituted the Main Study; additional adolescents were enrolled in the Adolescent Substudy to ensure enrollment of a total of 180 adolescent participants overall. Results are reported up to Week 16.

Participant flow — Overall Study
MilestoneAdults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Started264261260636060
Received study drug264261260626060
Completed244249250595860
Not completed201210420
Withdrew: Adverse event311010
Withdrew: Withdrawal by subject652100
Withdrew: Lost to follow-up322210
Withdrew: Other313000
Withdrew: Ongoing at time of analysis532100

Outcome measures

PrimaryMain Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 1626.4 (21.5 to 31.4)64.6 (59.1 to 70.0)77.1 (72.3 to 81.9)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 50.6 · 95% CI 43.8 to 57.4Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.1 · 95% CI 30.8 to 45.4Response Rate Difference = Upadacitinib - Placebo
PrimaryMain Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 1610.9 (7.4 to 14.4)39.6 (34.1 to 45.2)58.6 (53.0 to 64.2)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 47.6 · 95% CI 41.1 to 54.0Response rate difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 28.5 · 95% CI 22.1 to 34.9Response rate difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 1615.0 (10.9 to 19.0)51.7 (46.0 to 57.5)63.9 (58.4 to 69.4)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 48.8 · 95% CI 41.9 to 55.7Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 36.8 · 95% CI 29.7 to 43.8Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 1613.2 (9.4 to 17.0)42.8 (37.2 to 48.4)63.1 (57.6 to 68.6)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 49.9 · 95% CI 43.3 to 56.4Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 29.5 · 95% CI 22.8 to 36.3Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 4
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 415.0 (10.9 to 19.0)52.4 (46.7 to 58.2)65.6 (60.2 to 71.1)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 50.6 · 95% CI 43.8 to 57.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 37.4 · 95% CI 30.4 to 44.3Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving an EASI 75 Response at Week 4

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 4
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 414.8 (10.8 to 18.8)58.7 (53.1 to 64.2)72.4 (67.3 to 77.5)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 57.6 · 95% CI 51.2 to 63.9Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 43.8 · 95% CI 37.0 to 50.5Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving an EASI 75 Response at Week 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 26.9 (4.1 to 9.8)31.0 (25.8 to 36.2)44.1 (38.5 to 49.8)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 37.2 · 95% CI 31.0 to 43.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 24.0 · 95% CI 18.1 to 29.9Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving an EASI 90 Response at Week 4

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 4
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 44.9 (2.5 to 7.4)28.3 (23.2 to 33.4)43.8 (38.1 to 49.4)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.8 · 95% CI 32.8 to 44.8Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 23.3 · 95% CI 17.7 to 28.9Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a ranked secondary endpoint for participants in the Upadacitinib 30 mg + Topical Corticosteroids group versus Placebo + Topical Corticosteroids group only.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 161.3 (0.0 to 2.6)12.0 (8.3 to 15.7)22.6 (17.8 to 27.3)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 21.2 · 95% CI 16.3 to 26.1Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 1
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
percentage of participantsPlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 13.1 (1.1 to 5.0)12.2 (8.4 to 15.9)19.2 (14.7 to 23.8)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 16.2 · 95% CI 11.3 to 21.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 9.2 · 95% CI 4.9 to 13.4Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
percent changePlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16-25.07 (-31.64 to -18.49)-58.14 (-64.24 to -52.05)-66.85 (-72.99 to -60.72)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = <0.001 · Least squares (ls) mean difference: -41.79 · 95% CI -50.46 to -33.11Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -33.08 · 95% CI -41.72 to -24.44Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in EASI Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in EASI Score at Week 16
percent changePlacebo + Topical CorticosteroidsUpadacitinib 15 mg + Topical CorticosteroidsUpadacitinib 30 mg + Topical Corticosteroids
Main Study: Percent Change From Baseline in EASI Score at Week 16-45.86 (-50.09 to -41.63)-77.99 (-81.87 to -74.10)-87.31 (-91.20 to -83.41)
Statistical analysis
  • Placebo + Topical Corticosteroids vs Upadacitinib 30 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -41.45 · 95% CI -46.68 to -36.22Difference = Upadacitinib - Placebo
  • Placebo + Topical Corticosteroids vs Upadacitinib 15 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -32.13 · 95% CI -37.35 to -26.91Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 1630.3 (18.9 to 41.6)63.3 (51.1 to 75.5)84.3 (74.9 to 93.6)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.1 · 95% CI 38.8 to 67.4Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 32.7 · 95% CI 16.3 to 49.0Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 1611.2 (3.4 to 19.1)38.3 (26.0 to 50.6)67.4 (55.5 to 79.4)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 55.4 · 95% CI 41.4 to 69.5Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 26.3 · 95% CI 12.1 to 40.4Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1621.3 (11.0 to 31.6)45.6 (32.7 to 58.5)51.8 (38.7 to 64.9)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 30.5 · 95% CI 14.1 to 46.8Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.003 · Adjusted response rate difference: 24.5 · 95% CI 8.2 to 40.8Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 1620.7 (10.7 to 30.7)48.3 (35.7 to 61.0)73.6 (62.3 to 84.8)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 52.0 · 95% CI 37.3 to 66.7Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted response rate difference: 27.1 · 95% CI 11.1 to 43.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 4
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 423.0 (12.4 to 33.5)45.6 (32.7 to 58.5)46.4 (33.4 to 59.5)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.006 · Adjusted response rate difference: 23.5 · 95% CI 6.9 to 40.1Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.007 · Adjusted response rate difference: 22.7 · 95% CI 6.2 to 39.2Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 4
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 428.6 (17.4 to 39.7)54.9 (42.3 to 67.5)78.3 (67.9 to 88.8)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 49.3 · 95% CI 34.1 to 64.6Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.002 · Adjusted response rate difference: 26.2 · 95% CI 9.4 to 43.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 29.5 (2.3 to 16.8)33.7 (21.7 to 45.8)51.7 (39.0 to 64.3)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 41.5 · 95% CI 27.8 to 55.1Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted response rate difference: 24.4 · 95% CI 10.3 to 38.4Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 4
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 49.5 (2.3 to 16.8)34.2 (22.1 to 46.3)45.0 (32.4 to 57.6)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.9 · 95% CI 20.6 to 49.3Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted response rate difference: 24.5 · 95% CI 10.4 to 38.7Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16

EASI is used to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. and the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a secondary endpoint for participants in the Upadacitinib 30 mg + TCS group versus Placebo + TCS group only.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 164.8 (0.0 to 10.0)13.3 (4.7 to 21.9)25.0 (14.0 to 36.0)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted response rate difference: 19.8 · 95% CI 7.8 to 31.8Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 1
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
percentage of participantsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 19.8 (2.4 to 17.3)8.8 (1.4 to 16.1)16.1 (6.5 to 25.7)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.306 · Adjusted response rate difference: 6.2 · 95% CI -5.7 to 18.2Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Cochran-Mantel-Haenszel · p = 0.855 · Adjusted response rate difference: -1.0 · 95% CI -11.2 to 9.3Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
percent changeAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16-32.96 (-49.87 to -16.05)-59.34 (-75.78 to -42.90)-49.02 (-65.35 to -32.69)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = 0.180 · Ls mean difference: -16.05 · 95% CI -39.59 to 7.48Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = 0.029 · Ls mean difference: -26.38 · 95% CI -49.97 to -2.79Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in EASI Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in EASI Score at Week 16
percent changeAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
Adolescents: Percent Change From Baseline in EASI Score at Week 16-53.53 (-61.23 to -45.82)-77.90 (-85.36 to -70.44)-89.22 (-96.49 to -81.95)
Statistical analysis
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 30 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -35.69 · 95% CI -46.28 to -25.11Difference = Upadacitinib - Placebo
  • Adolescents: Placebo + Topical Corticosteroids vs Adolescents: Upadacitinib 15 mg + Topical Corticosteroids · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -24.37 · 95% CI -35.10 to -13.65Difference = Upadacitinib - Placebo

Adverse events

Collected over From first dose of study drug up to Week 16, or 30 days after last dose for participants who did not enter the blinded extension period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adults: Placebo + Topical Corticosteroids0/264 (0%)9/264 (3.4%)99/264 (37.5%)
Adults: Upadacitinib 15 mg + Topical Corticosteroids0/261 (0%)7/261 (2.7%)111/261 (42.5%)
Adults: Upadacitinib 30 mg + Topical Corticosteroids0/260 (0%)4/260 (1.5%)123/260 (47.3%)
Adolescents: Placebo + Topical Corticosteroids0/62 (0%)0/62 (0%)21/62 (33.9%)
Adolescents: Upadacitinib 15 mg + Topical Corticosteroids0/60 (0%)1/60 (1.7%)24/60 (40%)
Adolescents: Upadacitinib 30 mg + Topical Corticosteroids0/60 (0%)0/60 (0%)32/60 (53.3%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventAdults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
LIGAMENT RUPTUREInjury, poisoning and procedural complications0/2640/2610/2600/621/600/60
PANCYTOPENIABlood and lymphatic system disorders0/2640/2611/2600/620/600/60
CARDIAC FAILURE CONGESTIVECardiac disorders0/2640/2611/2600/620/600/60
ANAPHYLACTIC REACTIONImmune system disorders1/2640/2611/2600/620/600/60
ADENOCARCINOMA OF COLONNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2640/2611/2600/620/600/60
RETINAL DETACHMENTEye disorders0/2641/2610/2600/620/600/60
APPENDICITISInfections and infestations0/2641/2610/2600/620/600/60
PERITONSILLAR ABSCESSInfections and infestations0/2641/2610/2600/620/600/60
PHARYNGITIS STREPTOCOCCALInfections and infestations0/2641/2610/2600/620/600/60
OVERDOSEInjury, poisoning and procedural complications0/2641/2610/2600/620/600/60
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAdults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical Corticosteroids
ACNESkin and subcutaneous tissue disorders6/26425/26136/2601/628/609/60
NASOPHARYNGITISInfections and infestations31/26431/26137/2603/626/603/60
ORAL HERPESInfections and infestations5/2649/26122/2601/622/601/60
HEADACHENervous system disorders12/26411/26111/2604/625/604/60
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations21/26420/26119/2601/621/604/60
DERMATITIS ATOPICSkin and subcutaneous tissue disorders18/2648/2612/2604/623/600/60
VOMITINGGastrointestinal disorders2/2641/2610/2601/621/604/60
PYREXIAGeneral disorders3/2645/2613/2600/620/604/60
DIARRHOEAGastrointestinal disorders4/26410/2619/2604/621/603/60
STAPHYLOCOCCAL SKIN INFECTIONInfections and infestations1/2641/2611/2604/620/601/60

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
Mean37.2 ± 14.0835.0 ± 13.2938.3 ± 14.8215.1 ± 1.8515.4 ± 1.6515.3 ± 1.8632.8 ± 15.29
Age, Customized
Age, Customized(Participants)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
12 - 14 years00023142158
15 - 17 years000404639125
18 - < 40 years156176158000490
40 - < 65 years948085000259
≥ 65 years1451700036
Sex: Female, Male
Sex: Female, Male(Participants)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
Female10110495362725388
Male163157165273335580
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
Hispanic or Latino15211478772
Not Hispanic or Latino249240246565253896
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
American Indian or Alaska Native1230006
Asian52575814136200
Native Hawaiian or Other Pacific Islander0310004
Black or African American1515955655
White196177188444146692
More than one race07101211
Unknown or Not Reported0000000
Study Enrollment
Study Enrollment(Participants)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
Main Study264261260403937901
Adolescent Substudy00023212367
Geographic Region
Geographic Region(Participants)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
US/Puerto Rico/Canada909089313131362
Japan18161700051
China16151522151
Other140140139302728504
Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD)
Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD)(Participants)Adults: Placebo + Topical CorticosteroidsAdults: Upadacitinib 15 mg + Topical CorticosteroidsAdults: Upadacitinib 30 mg + Topical CorticosteroidsAdolescents: Placebo + Topical CorticosteroidsAdolescents: Upadacitinib 15 mg + Topical CorticosteroidsAdolescents: Upadacitinib 30 mg + Topical CorticosteroidsTotal
3 (Moderate)123124123282929456
4 (Severe)141137137353131512

2 further baseline measures are reported on the registry.

08

Study locations

193 sites

Showing the first 100 of 193 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Silverberg JI, Prajapati VH, Abraham S, Irvine AD, Gooderham MJ, Guttman-Yassky E, Tanizaki H, Rademaker M, Chen SH, Moreira A, Ta R, Lee WJ, Eyerich K. Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study. Dermatol Ther (Heidelb). 2026 Jul 30. doi: 10.1007/s13555-026-01865-0. Online ahead of print. PubMed 42530735 ↗
  • Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Gold LFS, de Bruin-Weller M, Bieber T, Kabashima K, Rosmarin D, Sancho C, Calimlim BM, Grada A, Yang Y, Wu X, Levy G, Raymundo EM, Teixeira HD, Silverberg JI. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025 Nov;26(6):1003-1016. doi: 10.1007/s40257-025-00975-3. Epub 2025 Sep 3. PubMed 40900410 ↗
  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28. PubMed 40875187 ↗
  • Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696. PubMed 39441580 ↗
  • Silverberg JI, Leshem YA, Calimlim BM, McDonald J, Litcher-Kelly L. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2023 Oct;39(10):1289-1296. doi: 10.1080/03007995.2023.2251883. Epub 2023 Sep 13. PubMed 37691437 ↗
  • Thyssen JP, Thaci D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, Kabashima K, Barbarot S, Luna PC, Xu J, Hu X, Liu Y, Raymundo EM, Calimlim BM, Nduaka C, Gamelli A, Simpson EL. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1871-1880. doi: 10.1111/jdv.19232. Epub 2023 Jun 21. PubMed 37247226 ↗
  • Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. PubMed 37043227 ↗
  • Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. PubMed 36754548 ↗
  • Silverberg JI, Simpson EL, Calimlim BM, Litcher-Kelly L, Li X, Sun X, Leshem YA. Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS). Dermatol Ther (Heidelb). 2022 Dec;12(12):2817-2827. doi: 10.1007/s13555-022-00836-5. Epub 2022 Nov 4. PubMed 36333616 ↗
  • Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. PubMed 35714786 ↗
  • Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21. PubMed 34023009 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Feb 2021, 30 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 30 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Jun 26, 2018
StartActual
Aug 9, 2018
Primary completionActual
Feb 16, 2021
CompletionEst.
Oct 23, 2030
Results first posted
Mar 31, 2022
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03568318
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Aug 9, 2018
Primary completion
Feb 16, 2021
Completion
Oct 23, 2030 (estimated)
Results posted
Mar 31, 2022
Last update
Dec 23, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Upadacitinib · Topical Corticosteroid

Start the discussion